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and the results of the meta-analysis less relevant 
in the context of the hypothesis that ongoing 
treatment with azithromycin would lead to sud-
den death from cardiovascular causes, as sug-
gested by the study involving Medicaid beneficia-
ries by Ray et al.
Brass argues that our conclusion is not sup-
ported by our results. Our conclusion was care-
fully phrased with the use of noncausal terminol-
ogy and is an accurate reflection of our findings 
that exposure was not associated with an in-
creased risk of the outcome. This reflects a sta-
tistical estimate that best fits the data, given the 
imposed statistical model.
However, like Brass, we think it is important 
to note that only a moderate-to-high relative in-
crease in the risk of death from cardiovascular 
causes (>55%) can be ruled out with a high de-
gree of certainty; this was explicitly stated in the 
Discussion section of our article.
Nevertheless, Brass raises important ques-
tions about terminology and the interpretation 
of statistical measures in medical research. We 
believe these questions extend far beyond the 
context of our specific study.
Henrik Svanström, M.Sc. 
Björn Pasternak, M.D., Ph.D. 
Anders Hviid, Dr.Med.Sci.
Statens Serum Institut 
Copenhagen, Denmark 
htr@ssi.dk
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
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Dr. Mosholder and a Colleague Reply: Mc-
Murray and Jhund correctly point out that mor-
tality was not increased in long-term placebo-con-
trolled trials of azithromycin for the prevention of 
atherosclerotic cardiac events. However, we draw 
only very limited reassurance from these data be-
cause of the design of the trials. In the six trials 
analyzed by Baker and Couch, the duration of 
azithromycin exposure relative to the follow-up 
time was different from that in the study by Ray 
et al., because patients received azithromycin only 
during a small fraction of the total days of fol-
low-up time. For example, in the Azithromycin 
and Coronary Events Study reported by Grayston 
et al., patients received azithromycin once a week 
for a year, and the median time to follow-up was 
3.9 years. Given that Ray et al. found a risk only 
on days with azithromycin use (days 1 through 
5 after the prescription), these long-term trials on 
cardiovascular prevention, as they were analyzed, 
are not suitable for assessing such an association 
with the rate of death from cardiovascular causes.
The comments by Brass reinforce the impor-
tance of considering not only the point estimate 
for a measure of risk, but also its confidence 
interval.
Andrew D. Mosholder, M.D., M.P.H. 
Sumathi Nambiar, M.D., M.P.H.
Food and Drug Administration 
Silver Spring, MD
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
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Effects of Medicaid on Clinical Outcomes
To the Editor: In a comprehensive and careful 
follow-up to their previous analysis,1 Baicker et al. 
(May 2 issue)2 report on the effects of insurance 
coverage on health care and health outcomes in 
the Oregon Medicaid lottery experiment after ap-
proximately 2 years. Their instrumental-variable 
analysis is the next best thing to a randomized, 
controlled trial, since the instrument — in this 
case, winning a lottery for Medicaid coverage — 
satisfies the large-sample properties of being 
correlated to treatment and not being correlated 
to the outcomes of interest (e.g., health care uti-
lization and outcomes) except through its effect 
on treatment.3
The financial effects on the lottery winners 
were not trivial. They received an in-kind bene-
fit valued at one third to two thirds of their 
household income, their out-of-pocket spend-
ing was reduced by 39% ($215), and catastroph-
ic expenditures were reduced by 81%. These 
financial consequences could have a direct ef-
fect on self-reported depression, other mental 
health conditions, and possibly other outcomes. It 
is telling that self-reported happiness increased 
in the first year after winning the lottery, but 
not in the second.1,2,4 Awarding lottery winners 
equivalents of cash prizes (worth approximately 
$6,600 each) rather than Medicaid might have 
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improved their health outcomes and well-being 
even more.
Joel W. Hay, Ph.D.
University of Southern California 
Los Angeles, CA 
jhay@usc.edu
No potential conflict of interest relevant to this letter was re-
ported.
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To the Editor: The abstract in the article by 
 Baicker et al. states that “Medicaid coverage gen-
erated no significant improvements in measured 
physical health.” This is a misleading summary 
of the data reported in their article. The best es-
timates are that the Medicaid group had better 
outcomes than the control group according to 
most measures (see Table 2 of the article). The 
problem is that these findings are not statisti-
cally significant.
So, the effects might have been zero. That is 
not the same as saying that they were zero, or 
even that they were small. Buried toward the end 
of the article is the statement, “The 95% confi-
dence intervals for many of the estimates of ef-
fects . . . include changes that would be con-
sidered clinically significant.”
Nevertheless, almost all the article, the relat-
ed editorial,1 and related news reports, opinion 
pieces, and online discussions proceeded as if 
the effects had been found to be zero.
If one objects, on the basis of a lack of statis-
tical certainty, to the simple summary that the 
Medicaid group had better outcomes, then one 
should describe the substantive meaning of the 
confidence interval. An honest summary is that 
it is quite likely there were positive effects, 
though it is possible that they were zero or 
negative.
Ross Boylan, Ph.D.
University of California, San Francisco 
San Francisco, CA 
ross@biostat.ucsf.edu
No potential conflict of interest relevant to this letter was re-
ported.
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To the Editor: Baicker et al. provide high-qual-
ity evidence of the failure of insurance to pro-
mote physical health even among the insured. 
One cause may be that insurers do not cover cost-
effective programs that reach beyond the thresh-
old of the physician’s office to change patient 
behavior,1 support patients at home,2 and alter 
systems of delivery.3
Even if they suggest that they support such 
interventions, insurers underinvest in them. For 
instance, for persons with diabetes, my own 
(generous) insurance covers only a handful of 
visits with a dietitian, and it offers neither tele-
phone-based reminders nor counseling on diet 
or exercise — far less than effective methods 
require.4
Public and private payers have tried to com-
pensate hospitals and physicians according to 
performance. Results have been decidedly mixed.5 
The reason may be not what they pay or how 
they pay it, but to whom. Insurers should be 
rewarded and penalized on the basis of compre-
hensive health outcomes (e.g., mortality, not just 
blood-pressure levels).
Insurers determine where funds flow. If we 
want the health system to care more about 
population health, we should make sure that 
insurers do too.
Ari B. Friedman, B.A.
University of Pennsylvania 
Philadelphia, PA 
abfriedman@gmail.com
No potential conflict of interest relevant to this letter was re-
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The Authors Reply: We appreciate the attention 
given to our study and agree with many of the 
comments. Our study indeed does not speak di-
rectly to the effects of different types of insur-
ance or of alternatives such as cash grants; these 
are important topics for future research.
Statistical precision is crucial to interpretation 
of the findings. The reported confidence intervals 
do not allow us to reject the null hypothesis that 
there was no effect of Medicaid on blood-pres-
sure, cholesterol, or glycated hemoglobin levels 
— but they are also consistent with Medicaid 
improving (or harming) these outcomes. Em-
pirical estimates always come with uncertainty. 
A key question is what effect sizes our findings 
rule out, and how these compare with findings 
from previous studies of the effect of health in-
surance or with expectations based on available 
treatments.
In some cases, we can reject effect sizes seen 
in previous studies. For example, we can reject 
decreases in diastolic blood pressure of more 
than 2.7 mm Hg (or 3.2 mm Hg in patients with 
a preexisting diagnosis of hypertension) with 
95% confidence. Quasi-experimental studies of 
the 1-year effect of Medicaid showed decreases 
in diastolic blood pressure of 6 to 9 mm Hg.1,2
In other cases, our confidence intervals do 
not rule out the health improvements one might 
expect given our estimate of the effect of Medic-
aid on medication use. For example, as noted in 
our article, given our estimate of the increase in 
the use of diabetes medication because of Med-
icaid, the clinical literature would predict a de-
crease in the average glycated hemoglobin level 
of 0.05 percentage points, an effect that is well 
within our 95% confidence interval.
We assessed conditions for which treatments 
exist that were effective within 2 years (our study 
period), but power is always constrained by sam-
ple size and is further reduced here by the im-
perfect take-up rates of Medicaid and lack of 
baseline clinical measures. We took several 
steps to increase power. Our study examined 
subgroups in which one might expect larger 
Medicaid effects (older persons and those with 
preexisting conditions) and we combined mea-
sures using the composite Framingham risk 
score. In none of these cases did we find sta-
tistically significant effects of Medicaid on 
physical health. We did find substantial and 
significant improvements in depression and fi-
nancial well-being, as well as an increased use of 
health care.
Katherine Baicker, Ph.D.
Harvard School of Public Health 
Boston, MA 
kbaicker@hsph.harvard.edu
Amy N. Finkelstein, Ph.D.
Massachusetts Institute of Technology 
Cambridge, MA
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
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Case 12-2013: A Woman with Pulmonary Infiltrates  
and Respiratory Failure
To the Editor: The Case Record presented by 
Hunt et al. (April 18 issue)1 describes a previ-
ously healthy 18-year-old woman with severe 
pneumonia due to herpes simplex virus type 1 
(HSV-1). It was speculated that the infection may 
have been acquired from her new boyfriend, and 
the HSV-1 infection was more likely to be pri-
mary than due to reactivation. The large number 
of infected cells in the bronchoalveolar-lavage 
fluid, the appearance of the alveolar cells on cy-
tologic examination, and the rapid response to 
therapy with acyclovir were cited as reasons for 
the diagnosis of probable primary HSV infection. 
Determination of the patient’s HSV IgG and IgM 
status would have further helped address this is-
sue. Although serum antibody against HSV-1 was 
positive, the type of antibody was not mentioned. 
A positive IgM (with negative IgG) would suggest 
primary infection, whereas a positive IgG (with 
negative IgM) would indicate HSV reactivation, 
either of which may have led to pneumonia and 
the crusted lesion on the patient’s lip. Also, clar-
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